Pharmaceutical Industry
CommentaryBayer CEO: Corporate bureaucracy belongs in the 19th century. Here’s how we’re fighting it
By Bill AndersonMarch 21, 2024
By Lindsey LeakeMarch 18, 2024
By Diane BradyMarch 14, 2024
HealthFDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
By Tom Murphy, Matthew Perrone and The Associated PressMarch 8, 2024
HealthMark Cuban’s $141K mistake: The Cost Plus Drugs cofounder says CEOs don’t understand health care coverage, and it’s costing them big
By Lindsey LeakeMarch 8, 2024
HealthBayer CEO compares the state of troubled pharma group to the time he fractured his leg skateboarding: ‘We’re badly broken in 4 places’
By Ryan HoggMarch 6, 2024
RetailNovo Nordisk’s Wegovy and Ozempic boom saved Denmark’s GDP from a no-growth 2023—and will help double its expected growth this year, country’s largest bank says
By Niclas Rolander and BloombergMarch 5, 2024
By Lindsey LeakeMarch 4, 2024
By Matthew Perrone and The Associated PressMarch 4, 2024
FinanceMeet Europe’s answer to the ‘Magnificent 7’—the high-flying ‘Granolas’ that Goldman Sachs is betting will prosper in the continent’s flatlining economy
By Ryan HoggMarch 3, 2024
LifestyleNovo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on ‘groundbreaking’ weight-loss drug trial results
By Prarthana PrakashFebruary 27, 2024
NewslettersDenmark, home to Ozempic-maker Novo Nordisk, is now Europe’s third-most prosperous economy
By Peter Vanham and Nicholas GordonFebruary 27, 2024
CommentarySanofi CEO: AI promises a great era of drug discovery that could fundamentally change medicine–but only if we allow it to deliver
By Paul HudsonFebruary 19, 2024
By Arthur Allen and KFF Health NewsFebruary 16, 2024
Most Popular
